Age differences in biological monitoring of chemical exposure: A tentative description using a toxicokinetic model

International Archives of Occupational and Environmental Health

Volumn 82, Issue 5, 2009, Pages 669-676

  Catherine, Tomicic ^a   Pierre Olivier, Droz ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Age; Biological indicators; Modeling; Toxicokinetic

Indexed keywords

AGE; ARTICLE; BIOLOGICAL MONITORING; COMPARTMENT MODEL; CONTROLLED STUDY; OCCUPATIONAL EXPOSURE; OCCUPATIONAL TOXICOLOGY; SIMULATION; TOXICOKINETICS;

ADULT; AGE FACTORS; AGED; COMPUTER SIMULATION; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; XENOBIOTICS;

EID: 63349087360     PISSN: 03400131     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00420-008-0366-5     Document Type: Article

References (37)

1. American Conference of Governmental Industrial Hygienists (ACGIH ®) (2007) TLV® s and BEI®s. ACGIH, Cincinnati
2. Anantharaju A, Feller A, Chedid A (2002) Aging liver. Gerontology 48:343-353. doi: 10.1159/000065506
3. Åstrand I (1983) Effect of physical exercise on uptake, distribution and elimination of vapors in man. In: Fiserova-Bergerova V (ed) Modeling of inhalation exposure to vapors: Uptake, distribution and elimination, vol 2. CRC Press, Boca Raton, pp 107-130
4. Berg UB (2006) Differences in decline in GFR with age between males and females. Reference data on clearances of inulin and PAH in potential kidney donors. Nephrol Dial Transplant 21:2577-2582. doi: 10.1093/ndt/ gfl227
5. Birnbaum LS (1991) Pharmacokinetic basis of age-related changes in sensitivity to toxicants. Annu Rev Pharmacol Toxicol 31:101-128. doi: 10.1146/annurev.pa.31.040191.000533
6. Chouker A, Martignoni A, Dugas M, Eisenmenger W, Schauer R, Kaufmann I et al (2004) Estimation of liver size for liver transplantation: The impact of age and sex. Liver Transplant 10(5):678-685. doi: 10.1002/ lt.20113
7. Clewell HJ, Teeguarden J, McDonald T, Sarangapani R, Lawrence G, Covington T et al (2002) Review and evaluation of the potential impact of age- and sex-specific pharmacokinetic differences on tissue dosimetry. Crit Rev Toxicol 32(5):329-389. doi: 10.1080/20024091064264
8. Clewell HJ, Gentry PR, Covington TR, Sarangapani R, Teeguarden JG (2004) Evaluation of the potential impact of age- and sex-specific pharmacokinetic differences on tissue dosimetry. Toxicol Sci 79:381-393. doi: 10.1093/toxsci/kfh109
9. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41. doi: 10.1159/000130554
10. Epstein M (1996) Aging and the kidney. J Am Soc Nephrol 7:1106-1122
11. Fagiolino P, Eiraldi R, Vàzquez M (2006) The influence of cardiovascular physiology on dose/pharmacokinetic and pharmacokinetic/ pharmacodynamic relationships. Clin Pharmacokinet 45(5):433-448. doi: 10.2165/00003088-200645050-00001
12. Ferrari AU, Radaelli A, Centola M (2003) Invited review: Aging and the cardiovascular system. J Appl Physiol 95:2591-2597
13. Geller AM, Zenick H (2005) Aging and the environment: A research framework. Environ Health Perspect 113(9):1257-1262
14. Hattis D, Ginsberg G, Sonawane B, Smolenski S, Russ A, Kozlak M et al (2003) Differences in pharmacokinetics between children and adults. II. Children's variability in drug elimination half-lives and in some parameters needed for physiologically-based pharmacokinetic modeling. Risk Anal 23(1):117-142. doi: 10.1111/1539-6924.00295
15. Jeandel C, Lapicque F, Netter P, Bannwarth B, Monot C, Gillet P et al (1992) Effect of age on the disposition of sodium fluoride. Eur J Clin Pharmacol 43(3):295-297. doi: 10.1007/BF02333026
16. Kreuzer PE, Csanédy GA, Baur C, Kessler W, Päpke O, Greim H et al (1997) 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and congeners in infants. A toxicokinetic model of human lifetime body burden by TCDD with special emphasis on its uptake by nutrition. Arch Toxicol 71(6):383-400. doi: 10.1007/s002040050402
17. Kyle UG, Genton L, Hans D, Karsegard L, Slosman DO, Pichard C (2001) Age-related differences in fat-free mass, skeletal muscle, body cell mass and fat mass between 18 and 94 years. Eur J Clin Nutr 55:663-672. doi: 10.1038/sj.ejcn.1601198
18. Le Couteur DG, McLean AJ (1998) The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 34(5):359-373. doi: 10.2165/00003088-199834050-00003
19. Lin YS, Kupper LL, Rappaport SM (2005) Air samples versus biomarkers for epidemiology. Occup Environ Med 62:750-760. doi: 10.1136/oem.2004.013102
20. Löf A, Johanson G (1998) Toxicokinetics of organic solvents: A review of modifiying factors. Crit Rev Toxicol 28(6):571-650. doi: 10.1080/10408449891344272
21. Mangoni AA, Jackson SHD (2003) Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications. Br J Clin Pharmacol 57(1):6-14. doi: 10.1046/j.1365-2125.2003.02007.x
22. McLean AJ, Le Couteur DG (2004) Aging biology and geriatric clinical pharmacology. Pharmacol Rev 56:163-184. doi: 10.1124/pr.56.2.4
23. Mühlberg W, Platt D (1999) Age-dependent changes of the kidneys: pharmacological implications. Gerontology 45:243-253. doi: 10.1159/ 000022097
24. O'Flaherty EJ (1998) A physiologically based kinetic model for lead in children and adults. Environ Health Perspect 106(Suppl 6) 1495-1503
25. Pierrehumbert G, Droz PO, Tardif R, Charest-Tardif G, Truchon G (2002) Impact of human variability on the biological monitoring of exposure to toluene, phenol, lead, and mercury. II. Compartimental based toxicokinetic modeling. Toxicol Lett 134:165-173. doi: 10.1016/ S0378-4274(02)00186-8
26. Ribera-Casado JM (1999) Ageing and the cardiovascular system. Z Gerontol Geriatr 32:412-419. doi: 10.1007/s003910050138
27. Rodeheffer RJ, Gerstenblith G, Becker LC, Fleg JL, Weisfeldt ML, Lakatta EG (1984) Exercise cardiac output is maintained with advancing age in healthy human subjects: Cardiac dilatation and increased stroke volume compensate for a diminished heart rate. Circulation 69(2):203-213
28. Schmucker DL (2001) Liver function and phase I drug metabolism in the elderly - A paradox. Drugs Aging 18(11):837-851. doi: 10.2165/ 00002512-200118110-00005
29. Silva FG (2005) The aging kidney: A review - part I. Int Urol Nephrol 37:185-205. doi: 10.1007/s11255-004-0873-6
30. Snyder WS, Cook MJ, Karhausen LR, Nasset ES, Parry Howells G, Tipton IH (1975) Report of the Task Group on Reference Man. International Commission on Radiological Protection (ICRP) no. 23
31. Tardif R, Droz PO, Charest-Tardif G, Pierrehumbert G, Truchon G (2002) Impact of human variability on the biological monitoring of exposure to toluene. I. Physiologically based toxicokinetic modeling. Toxicol Lett 134:155-163. doi: 10.1016/S0378-4274(02)00185-6
32. Tonner PH, Kampen J, Scholz J (2003) Pathophysiological changes in the elderly. Best Pract Res Clin Anaesthesiol 17(2):163-177. doi: 10.1016/ S1521-6896(03)00010-7
33. Truchon G, Tardif R, Droz PO, Charest-Tardif G, Pierrehumbert G, Drolet D (2003) Quantification of biological variability using modeling-development of a strategy guide for biological exposure monitoring (in French). Études et recherches/Rapport R-337, Montréal, IRSST, 275 pp
34. Truchon G, Perrault G, Tardif R (2004) Toxicologie industrielle et vieillissement. Pistes 6(1)
35. Truchon G, Tardif R, Droz PO, Charest-Tardif G, Pierrehumbert G (2006) Biological exposure indicators: Quantification of biological variability using toxicokinetic modeling. J Occup Environ Hyg 3:137-143. doi: 10.1080/15459620500524987
36. Turnheim K (2003) When drug therapy gets old: Pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 38:843-853. doi: 10.1016/ S0531-5565(03)00133-5
37. Zoli M, Magalotti D, Bianchi G, Gueli C, Orlandini C, Grimaldi M et al (1999) Total and functional hepatic blood flow decrease in parallel with ageing. Age Ageing 28:29-33. doi: 10.1093/ageing/28.1.29